Dow Jones
38 353,44 -150,25 (-0,39 %) Nasdaq
15 645,26 -51,38 (-0,33 %) Nikkei 225
38 460,08 +907,92 (+2,42 %) EUR/USD
1,0688 -0,0016 (-0,15 %) HANG SENG
17 201,27 +372,34 (+2,21 %) Bitcoin EUR
60 395,48 -1 962,74 (-3,15 %)
BioNTech SE (BNTX)
BioNTech SE
An der Goldgrube 12
Mainz 55131
Germany
49 6131 9084 0
https://www.biontech.de
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 6 133
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Dr. Ugur Sahin M.D. | Co-Founder, CEO & Chair of the Management Board | 1,23M | S.O. | 1965 |
| Dr. Ozlem Tureci M.D. | Co-Founder, Chief Medical Officer & Member of Management Board | 808,61k | S.O. | 1967 |
| Mr. Jens H. Holstein | CFO & Member of Management Board | 1,42M | S.O. | 1963 |
| Dr. Sierk Poetting Ph.D. | MD, COO & Member of Management Board | 830,98k | S.O. | 1973 |
| Mr. Ryan Richardson | Chief Strategy Officer, MD & Member of Management Board | 1,02M | S.O. | 1979 |
| Mr. Sean Marett | Chief Business Officer, Chief Commercial Officer & Member of Management Board | 802,22k | S.O. | 1965 |
| Dr. James Timothy Patrick Ryan Ph.D. | Chief Legal Officer & Member of the Management Board | 600,86k | S.O. | 1975 |
| Mr. Zach Taylor | Senior Vice President of Corporate Development & Strategy | S.O. | S.O. | S.O. |
| Dr. Katalin Kariko Ph.D. | Senior VP & External Consultant for RNA Protein Replacement Therapies | S.O. | S.O. | S.O. |
| Dr. Oliver Henning Ph.D. | Senior Vice President of Operations | S.O. | S.O. | S.O. |
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
Gouvernance d’entreprise
L’ISS Governance QualityScore de BioNTech SE en date du 1 avril 2024 est 5. Les scores principaux sont Audit : 6; Société : 3; Droits des actionnaires : 1; Compensation : 7.
